Q3 2017 VIVUS Inc Earnings Call

7/11/2017 16:30

Conference Call VIVUS Inc

VIVUS Inc Conference call will be held on Nov 7, 2017. During the earnings conference call's session VIVUS Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact VIVUS Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
VIVUS is a biopharmaceutical company with two therapies approved by the FDA: Qsymia® (phentermine and topiramate extended­release) for chronic weight management and STENDRA® (Avanafil) for erectile dysfunction, or ED. STENDRA is also approved by the European Commission, or EC, under the trade name, SPEDRA, for the treatment of ED in the EU. Qsymia was approved by the FDA in July 2012 as an adjunct to a reduced­calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index, or BMI, of 30 or greater, or obese patients, or a BMI of 27 or greater, or overweight patients, in the presence of at least one weight­related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol, or dyslipidemia. Qsymia incorporates a proprietary formulation combining low doses of active ingredients from two previously approved drugs, phentermine and topiramate.    
Read more Conference Call

VIVUS Inc (VVUS)

351 East Evelyn Avenue, Mountain View California 94041, United States